Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 24Genitourinary 3Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Renal Cell 84Kidney Neoplasms 22Prostatic Neoplasms 14Neoplasm Metastasis 10Neoplasms 9Urinary Bladder Neoplasms 8Carcinoma, Hepatocellular 5Liver Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma 3Urethral Neoplasms 2Sarcoma 2Multiple Myeloma 2Hematologic Neoplasms 2Glioblastoma 2Financial Stress 2Wilms Tumor 1Ureteral Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Germ Cell and Embryonal 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × Sorafenib × Genitourinary × Clear all
NCT00418496 2017-02-20

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
17 enrolled
DermatologicGenitourinary

Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
87 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡